Who are Capsulomics's investors?

Capsulomics's investors include Early Light Ventures, Maryland TEDCO, TEDCO, Gaingels, Riptide Ventures.

How much funding has Capsulomics raised?

Capsulomics has disclosed $2.4M raised across 1 of its 3 known rounds.

Where is Capsulomics headquartered?

Capsulomics is headquartered in Halethorpe, US.

Capsulomics

Halethorpe, US · Maryland corporation · 6 known investors

Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.

AI & Machine Learning Biotech Digital Health Medical Devices

Founders & leadership

Daniel LunzinExecutive

William StevensExecutive

Stephen MeltzerNamed on SEC filing

Board

John NeiderhuberBoard director

Investors · 6

Early Light VenturesBaltimore · $100K – $500K

Maryland TEDCOUpper Marlboro · $500K – $1.5M

TEDCOColumbia

GaingelsreportedNew York · $200K – $500K

Riptide VenturesreportedBaltimore · $750K

Also in the syndicate · 1

Wexford Science and Technology

Funding

SEC filings, press & company announcements

$2.4M disclosed across 1 of 3 rounds · 2019–2023

Undisclosed amountseed roundMar 2023
Gaingels, Riptide Ventures, TEDCO, Wexford Science and Technology
Source ↗
Undisclosed amountseed roundMar 2022
Source ↗

▶$2.4MraisedMar 2025 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John NeiderhuberDirector
Daniel LunzExecutive Officer, Director
William StevensExecutive Officer
Stephen MeltzerDirector

Offering amount: $3M
Amount sold: $2.4M
First sale: Dec 2019
Incorporated: Corporation, Maryland
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Good News: Haystack Oncology Acquired, Scene Health Raises $17.7M - Johns Hopkins Technology Venturesventures.jhu.edu · Jun 2023

PREVISE CLOSES $3M SEED TO TACKLE EARLY CANCER DETECTION AND LAUNCHES COMPANY'S FIRST ESOPHAGEAL CANCER PROGNOSTIC TEST - BioSpacebiospace.com · Mar 2023

Previse Closes $3M in Seed Fundingfinsmes.com · Mar 2023

Power Moves: Capsulomics nabs ex-Delfi Diagnostics CFOtechnical.ly · Mar 2022

Tech startup Capsulomics hires former PGDx CFO Bill Stevens as it looks to raise seed round - Baltimore Business Journalbizjournals.com · Mar 2022

Capsulomics establishes $3.7 Million NIH-funded research collaboration with Johns Hopkins Universityprnewswire.com · Feb 2020

Frequently asked questions

What does Capsulomics do?: Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
Who are Capsulomics's investors?: Capsulomics's investors include Early Light Ventures, Maryland TEDCO, TEDCO, Gaingels, Riptide Ventures.
How much funding has Capsulomics raised?: Capsulomics has disclosed $2.4M raised across 1 of its 3 known rounds.
Where is Capsulomics headquartered?: Capsulomics is headquartered in Halethorpe, US.